Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

@article{Sestak2010EffectOB,
  title={Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.},
  author={Ivana Sestak and Wolfgang Distler and John F. Forbes and Mitch Dowsett and Anthony Howell and Jack Cuzick},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 21},
  pages={3411-5}
}
PURPOSE Third-generation aromatase inhibitors have been widely used in postmenopausal women for the adjuvant treatment of hormone receptor-positive breast cancer. As aromatase inhibitors work by inhibiting the conversion of androgens to estrogens in adipose tissue, we hypothesized that anastrozole may be more effective in women with a high body mass index (BMI). PATIENTS AND METHODS The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized clinical trial in… CONTINUE READING